Karyopharm Therapeutics
Shane W. Miller possesses extensive experience in clinical research management, having held various roles in prominent organizations. Shane served as a Clinical Project Manager and Senior Clinical Trial Manager at Karyopharm Therapeutics Inc. Previously, Shane excelled as a Senior Clinical Trial Associate and Research Manager at both Corbus Pharmaceuticals and the Baim Institute for Clinical Research. Additionally, Shane contributed to Parexel International as a Clinical Trial Specialist II (CTS II) and began a career in clinical research as a Clinical Research Coordinator at 21st Century Oncology.
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).